Fan Z, Masui H, Altas I, Mendelsohn J
Laboratory of Receptor Biology, Memorial Sloan-Kettering Cancer Center, New York, New York 10021.
Cancer Res. 1993 Sep 15;53(18):4322-8.
We have previously described anti-epidermal growth factor (EGF) receptor monoclonal antibodies (MAbs) which can block binding of transforming growth factor alpha (TGF-alpha) and EGF to receptors and inhibit activation of receptor tyrosine kinase. Studies with these MAbs involving cell cultures and nude mouse xenografts demonstrated their capacity to inhibit the growth of a variety of tumor cell lines, which express EGF receptors and TGF-alpha and appear to depend upon receptor activation for cell proliferation. To explore the mechanism(s) by which anti-EGF receptor 225 MAb inhibits cell proliferation, we have compared the activity of native 225 MAb with the response to bivalent 225 F(ab')2 and monovalent 225 Fab' fragments. Both native 225 MAb and its fragments could inhibit the binding of 125I-EGF to EGF receptors. Scatchard analysis revealed that the Kd of 225 F(ab')2 is comparable to that of 225 MAb (1 nM), whereas the Kd of 225 Fab' is 5 nM. Both bivalent 225 MAb and 225 F(ab')2 and monovalent 225 Fab' were able to completely inhibit TGF-alpha-induced EGF receptor tyrosine kinase activation, as assayed by autophosphorylation of tyrosine residues of EGF receptors on MCF10A nonmalignant human mammary cells, MDA468 human breast adenocarcinoma cells, and A431 human vulvar squamous carcinoma cells. The bivalent forms of MAb could inhibit proliferation stimulated by endogenous (autocrine) TGF-alpha in cultures of these three cell lines. They also blocked growth stimulation by added exogenous TGF-alpha in cultures of MCF10A cells and the growth-inhibitory effect of exogenous TGF-alpha upon MDA468 and A431 cell cultures. Monovalent 225 Fab' had weaker inhibitory effects upon the proliferation of these cell lines. To determine whether the in vivo antiproliferative activity of anti-EGF receptor MAb can occur without the participation of the Fc portion of MAb, the capacities of 225 F(ab')2 and native 225 MAb to inhibit growth of s.c. A431 cell xenografts were compared. Equimolar amounts of either 225 MAb or 225 F(ab')2 were administered at intervals equivalent to the half-lives of the molecules, to attempt to maintain comparable plasma levels. Both 225 MAb and 225 F(ab')2 inhibited A431 cell xenograft growth in a dose-dependent manner, with a more sustained response in the case of the intact antibody.(ABSTRACT TRUNCATED AT 400 WORDS)
我们之前曾描述过抗表皮生长因子(EGF)受体单克隆抗体(MAb),其可阻断转化生长因子α(TGF-α)和EGF与受体的结合,并抑制受体酪氨酸激酶的激活。对这些MAb进行的涉及细胞培养和裸鼠异种移植的研究表明,它们能够抑制多种肿瘤细胞系的生长,这些肿瘤细胞系表达EGF受体和TGF-α,并且其细胞增殖似乎依赖于受体激活。为了探究抗EGF受体225 MAb抑制细胞增殖的机制,我们比较了天然225 MAb与二价225 F(ab')2和单价225 Fab'片段的活性。天然225 MAb及其片段均可抑制125I-EGF与EGF受体的结合。Scatchard分析显示,225 F(ab')2的解离常数(Kd)与225 MAb相当(1 nM),而225 Fab'的Kd为5 nM。通过检测MCF10A非恶性人乳腺细胞、MDA468人乳腺腺癌细胞和A431人外阴鳞状癌细胞中EGF受体酪氨酸残基的自磷酸化情况,发现二价225 MAb和225 F(ab')2以及单价225 Fab'均能完全抑制TGF-α诱导的EGF受体酪氨酸激酶激活。MAb的二价形式可抑制这三种细胞系培养物中内源性(自分泌)TGF-α刺激的增殖。它们还可阻断MCF10A细胞培养物中添加的外源性TGF-α的生长刺激作用,以及外源性TGF-α对MDA468和A431细胞培养物的生长抑制作用。单价225 Fab'对这些细胞系增殖的抑制作用较弱。为了确定抗EGF受体MAb的体内抗增殖活性是否可在不依赖MAb的Fc部分参与的情况下发生,我们比较了225 F(ab')2和天然225 MAb抑制皮下A431细胞异种移植生长的能力。以相当于分子半衰期的间隔给予等摩尔量的225 MAb或225 F(ab')2,试图维持相当的血浆水平。225 MAb和225 F(ab')2均以剂量依赖性方式抑制A431细胞异种移植的生长,完整抗体的反应更持久。(摘要截短至400字)